Company: ADPT
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001193125-25-103752
Chunk: 20

Company: Adaptive Biotechnologies Corp
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 20
---
 by SEC rules to be included in our annual proxy statement. |

| • |     | Reviewing related person transactions for potential conflict of interest situations and approving such transactions in accordance with our policies. |

| • |     | Reviewing content and talking points of our quarterly earnings releases in parallel with the full board of directors. |

In addition, the audit committee periodically reviews our insider trading policy, which prohibits short sales, pledging, hedging or other monetization transactions, and other transactions which would, if consummated, allow insiders to continue to own our securities without the full risks and rewards of ownership. See also the section entitled “ Insider Trading Policy”elsewhere in this Proxy. Compensation and Human Capital Committee Service and Responsibilities Robert Hershberg, PhD, MD, Peter Neupert and Katey Owen, PhD serve on the compensation and human capital committee, chaired by Dr. Hershberg. The committee met four times during 2024. Our board of directors has determined that each member of the compensation and human capital committee during 2024 was and is “independent” as that term is defined in Nasdaq rules and is a “non-employeedirector” under Rule 16b-3under the Exchange Act. In addition, our board of directors has determined that Dr. Hershberg, Mr. Neupert and Dr. Owen each meet the heightened independence requirements for compensation and human capital committee purposes under Section 10C of the Exchange Act and related SEC and Nasdaq rules. The compensation and human capital committee’s responsibilities include:

| • |     | Reviewing and approving our philosophy, strategies, policies and plans with respect to the compensation of our Chief Executive Officer and our other executive officers. |

| • |     | Making recommendations to our board of directors with respect to the compensation of our Chief Executive Officer and our other executive officers. |

| • |     | Reviewing and assessing the independence of compensation advisors. |

| • |     | Overseeing and administering our equity incentive plans. |

| • |     | Preparing the compensation and human capital committee reports required by the SEC, including our “Compensation Discussion and Analysis” disclosure. |

14

Nominating and Corporate Governance Committee Service and Responsibilities Michael Pellini, MD, and Peter Neupert serve on the nominating and corporate governance committee, chaired by Mr. Neupert. The nominating and corporate governance committee met once during 2024. Our board of directors has determined that each of Dr. Pellini and Mr. Neupert is “